Blog
A Historic Day in Medicine: VERVE-102 Data for Cholesterol
A historic day in medicine — today my brother Scott presented data to the European Atherosclerosis Society (EAS) on VERVE-102, a base-editing therapy targeting PCSK9 to treat high cholesterol. After a single dose, patients experienced a permanent, highly significant reduction in cholesterol levels without significant adverse effects. The results were published concurrently in the New England Journal of Medicine, with Scott as first author — a huge accomplishment after years of hard work and sacrifice, and a genuinely exciting development for how we'll care for cardiovascular disease patients in the years ahead.
Key Highlights
- Therapy: VERVE-102, a base-editing treatment that permanently edits the PCSK9 gene to lower cholesterol.
- Result: A single dose produced a permanent, highly significant reduction in cholesterol with no significant adverse effects.
- Publication: Findings published concurrently in the New England Journal of Medicine (NEJM).
- Presented at: The European Atherosclerosis Society (EAS) congress.
Journal Article: New England Journal of Medicine — In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia
Source: Facebook — Jonathan Vafai, MD
Have questions about the conditions we treat, or ready to see Dr. Vafai? Learn about our care or schedule a visit.